ANAPTYSBIO, INC (ANAB)
AnaptysBio used to be a clinical-stage immunology company hunting for the next blockbuster antibody. After years burning cash on drug development, the company pivoted dramatically in early 2026: it spun off all its remaining biopharma operations into a separate public company called First Tracks Biotherapeutics and transformed itself into a royalty manager.
The shift was fundamental. ANAB now exists to milk two partnerships rather than invent new medicines. On one side sits Jemperli, a drug licensed to GlaxoSmithKline for autoimmune and inflammatory indications. On the other is imsidolimab, an asset in a collaboration with Vanda that targets similar patient populations. The company’s stated purpose is blunt: “Protect and return value” through the royalty streams flowing from these agreements.
This is a recognizable playbook in biotech. When a company’s pipeline matures into disappointment or plateaus at clinical trial, a common exit is to strip out the promising assets, spin them to a fresh entity with a war chest, and leave the parent holding the royalty rights. For shareholders in ANAB, this means no more speculative drug-development risk, but also no upside from a transformative approval. Instead, the company collects downstream payments whenever GSK or Vanda hit commercial milestones or sell doses.
The spin-off gave First Tracks roughly $180 million in cash to fund three programs: ANB033, a CD122 antagonist for celiac disease and eosinophilic esophagitis; rosnilimab, a T-cell depleter that finished Phase 2b for rheumatoid arthritis; and ANB101, a BDCA2 modulator in early trials. That was the company’s past incarnated as a fresh, better-capitalized startup.
For ANAB shareholders, the trade-off is between the upside of a speculative biotech and the stability of a passive income stream. The royalty model trades growth optionality for near-term cash flow certainty, provided GSK and Vanda stay the course with their commercialization plans.
Active partnerships:
- Jemperli partnership with GlaxoSmithKline
- Imsidolimab partnership with Vanda